We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

This study is currently recruiting participants.
Verified October 2017 by Ana Gugila, Assurex Health Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02466477
First Posted: June 9, 2015
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Programs for Assessment of Technology in Health Research Institute
Centre for Addiction and Mental Health
Genome Canada
Assurex Health Ltd.
Mars Excellence in Clinical Innovation and Technology Evaluation
Information provided by (Responsible Party):
Ana Gugila, Assurex Health Inc.
  Purpose
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder (MDD) patient outcomes following use of the GeneSight Psychotropic (GEN) test. The first objective of this trial is to utilize a double-blinded, randomized clinical trial design to replicate previous findings of improvement in clinical outcomes in MDD subjects whose medication therapy was guided by GEN testing. Another objective is to determine the added benefit of Enhanced-GeneSight (E-GEN) compared to GEN for the pharmacogenomic guidance of treatment selections. Furthermore, this trial intends to develop an evidence-based case for the value of GEN and E-GEN to Canadian healthcare payers.

Condition Intervention Phase
Depressive Disorder, Major Depression Depressive Disorder Genetic: GeneSight Psychotropic (GEN) Genetic: Enhanced-GeneSight Psychotropic (E-GEN) Other: Treatment as Usual (TAU) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic

Further study details as provided by Ana Gugila, Assurex Health Inc.:

Primary Outcome Measures:
  • Change in depressive symptoms as assessed by the 17-item Hamilton Depression (HAM-D17) score [ Time Frame: From baseline to Week 8 ]
    Mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to Week 8 of the study


Secondary Outcome Measures:
  • Change in depressive symptoms as assessed by the 16-Item Clinician Quick Inventory of Depressive Symptomatology (QIDS-SR16) [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
  • Change in depressive symptoms as assessed by the 9-Item Patient Health Questionnaire (PHQ-9) [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
  • Change in anxiety symptoms as assessed by theGeneralized Anxiety Disorder 7-Item (GAD-7) Scale [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
  • Change in severity of illness as assessed by the Clinical Global Impression of Severity (CGI-S) [ Time Frame: Baseline, Week 12 and Month 12 ]
  • Change in global improvement as assessed by the Clinical Global Impression of Improvement (CGI-I) [ Time Frame: Week 12, and Month 12 ]
  • Change in global therapeutic benefit and global severity of side effects as assessed by the Clinical Global Impression Efficacy Index [ Time Frame: Week 12 and Month 12 ]
  • Changes to initial prescribing based on availability of pharmacogenomic data [ Time Frame: Screening and Baseline ]
  • Response rates to psychotropic medication [ Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12 ]
    A responder is defined as a participant with 50% decrease in HAM-D17 score from baseline.

  • Remission rates [ Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12 ]
    A remitter is defined as a participant with HAM-D17 score equal or less that 7.

  • Time to response [ Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12 ]
  • Time to remission [ Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12 ]
  • Change in psychotropic medication side effects as assessed by the Udvalg for Kliniske Undersogeler (UKU) Side Effect Rating Scale [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
  • Change in global measure of side effects (frequency, intensity, and burden domains) as assessed by the Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
  • Weight gain [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
    Subject's weight

  • Waist-to-hip ratio [ Time Frame: Baseline, Weeks 8 and 12, and Month 12 ]
    Subject's waist and hip measurements

  • Change in health related quality of life as assessed by the EuroQol (EQ-5D-5L) [ Time Frame: Baseline, Week 12, Months 6, 9 and 12 ]
  • Change in health related quality of life as assessed by the Short Form (36) Health Survey (SF-36) [ Time Frame: Baseline, Week 12, Months 6, 9 and 12 ]
  • Pharmacogenetics in Psychiatry Follow-up Questionnaire (PIPFQ) [ Time Frame: Baseline, when prescription changes are made (expected average of every 4 weeks), and Month 12 ]
    The PIPFQ is a questionnaire developed by CAMH to evaluate each physician's attitude and experience to pharmacogenomic testing. Information is solicited from the physician on three different domains: the processing of the physician's last referral, the contact and outcome of the physician's patient, and the physician's perspective on the future of genetic studies in psychiatric drug treatment.

  • Healthcare resource utilization (Composite measure of healthcare costs): physician visits, hospital utilization, emergency department visits, medication use, and laboratory tests [ Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12 ]
  • Productivity losses (measured as economic costs) [ Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12 ]

Estimated Enrollment: 570
Actual Study Start Date: June 2015
Estimated Study Completion Date: November 2020
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GeneSight Psychotropic (GEN)
The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
Genetic: GeneSight Psychotropic (GEN)
Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
Experimental: Enhanced-GeneSight Psychotropic (E-GEN)
The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
Genetic: Enhanced-GeneSight Psychotropic (E-GEN)
The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
Active Comparator: Treatment as Usual (TAU)

The comparator chosen for this study provides a "real world" comparison of standard of care for patients who receive no pharmacogenomics guidance.

Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians.

Other: Treatment as Usual (TAU)
Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.

Detailed Description:

The primary objectives of this study are 1) to compare the efficacy of GEN to treatment as usual (TAU) in improving response to psychotropic treatment in outpatients suffering from a MDD and having had - within the current episode - an inadequate response to at least one psychotropic medication included in GEN; and 2) to validate the utility of the new CAMH markers and demonstrate the superior predictive capabilities and greater clinical utility of E-GEN as compared to GEN.

This study is designed as a three-arm multi-centre, double-blind (participants and raters), randomized controlled trial to compare the clinical and economic outcomes of GEN, E-GEN and TAU for patients suffering from a MDD and having had - within the current episode - an inadequate response to at least one psychotropic medication included in GEN. Participants will be randomized in a 1:1:1 ratio to each of the three treatment arms. Recruitment will be 24 months. Follow-up will be 12 months.

Subjects will complete short diagnostic interviews specific to their clinical diagnosis, basic metabolic measures (eg. blood pressure, weight), and provide buccal swab samples for genetic analysis (the unanalyzed buccal swabs and associated DNA will be biobanked). During the first visit, blood and urine samples will be required for laboratory panel screening and blood biobanking. Subjects will be monitored over a one year period and clinical measures and healthcare resource utilization will be obtained. Treating clinicians in the GEN and E-GEN arms will receive an easy to implement report providing pharmacogenomic guidance for prescribing psychotropic medications to their patients.

The study will recruit subjects from 10 sites, stratified into 2 clusters. Nine study sites altogether will form one of the two stratified clusters. CAMH will constitute the tenth study site and the second stratified cluster.The sample size required for this study was calculated using effect size estimates drawn from a previous study conducted by Hall-Flavin et al [Pharmacogenetics Genomics 2013; 23(10)]. Assuming an effect size of 0.30 in HAM-D17 score favoring the treatment group, intra class coefficient between clusters of 20%, statistical power of 90%, an alpha level of 0.05, and an expected 16.7% rate of premature discontinuation by Week 8 (primary endpoint), a total of 570 subjects (i.e., 190 per treatment arm) are required to detect the same effect in this study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older;
  • Suffer from a Major Depressive Episode meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;
  • Have had an inadequate response within the current episode to at least one psychotropic treatment in GEN. Inadequate response is defined as inadequate efficacy after 6 weeks of a psychotropic treatment or discontinuation of a psychotropic treatment due to adverse events (AEs) or intolerability;
  • Have each a score on the 16-item Clinician Quick Inventory of Depressive Symptomatology (QIDS-C16) and 16-item Self-Report Quick Inventory of Depressive Symptomatology (QIDS-SR16) rating scales ≥ 11;
  • Be able to understand the requirements of the study and provide written informed consent to participate in this study;
  • Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests.

Exclusion Criteria:

  • Patients posing a serious suicidal risk and/or in need of immediate hospitalization as judged by the Investigator;
  • Patients with a diagnosis of Bipolar I or II disorder;
  • Patients with a current Axis I diagnosis of:

    • Delirium
    • Dementia
    • Amnestic and/or other cognitive disorder
    • Schizophrenia or other psychotic disorder;
  • Patients having experienced hallucinations, delusions, or any psychotic symptomatology within the current depressive episode or during prior depressive episodes;
  • Patient is currently in an inpatient facility;
  • Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for at least 6 months;
  • Patients who meet DSM-IV-TR criteria for any significant current substance use disorder;
  • Patients with:

    • hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;
    • malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;
    • significant unstable medical condition or life threatening disease with - need for therapies that may obscure the results of treatment and/or of the study;
  • Participation in another clinical trial within 30 days of the screening visit;
  • Anticipated inability to attend scheduled study visits;
  • Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;
  • Patients with a history of prior pharmacogenomic testing;
  • Any change in psychotropic medication (including change in dosage) between screening and baseline;
  • Patients currently receiving electroconvulsive therapy (ECT), deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) treatments, or currently scheduled to receive maintenance treatments of ECT, DBS, or TMS during the course of the study;
  • Patients who self-report to be pregnant or lactating;
  • Patients with a history of gastric bypass surgery.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02466477


Contacts
Contact: Deseree Wong, MBA 416-626-2671 ext 4425 deseree.wong@topstoneresearch.com

Locations
Canada, Ontario
Chatham-Kent Clinical Trials Research Center Recruiting
Chatham, Ontario, Canada, N7L 1B7
Contact: Julie Anderson Anderson Handsor, RPN,CCRP    519-397-3791 ext 22909 or 2291    jandersonhandsor@ckha.on.ca   
Principal Investigator: Ranjith D Chandrasena, M.D, F.R.C.P         
Sub-Investigator: Siva Devarajan, M.D, F.R.C.P         
Sub-Investigator: Robert F Fairbairn, M.D, F.R.C.P         
Hamilton Community Health Centre Family Health Organization Recruiting
Hamilton, Ontario, Canada, L8L 5G8
Contact: Adrienne Ziemer    905 529 1221    adrienneziemer@gmail.com   
Hamilton Medical Research Group Recruiting
Hamilton, Ontario, Canada, L8M 1K7
Contact: Simone Leung    905-545-1376 ext 211    simone.leung@hmrg.org   
St. Joseph's Healthcare Hamilton (SJHH) Recruiting
Hamilton, Ontario, Canada, L8N 3K7
Contact: Benicio Frey, MD, MSc, PhD    905-522-1155 ext 33605    freybn@mcmaster.ca   
Principal Investigator: Benicio Frey, MD, MSc, PhD         
Sub-Investigator: Luciano Minuzzi, MD, PhD         
Sub-Investigator: Gary Hasey, MD         
Milestone Research Recruiting
London, Ontario, Canada, N5W6A2
Contact: Tarra Griffin    (519)659-4040    tara@milestoneresearch.ca   
London Health Sciences Centre Completed
London, Ontario, Canada, N6A 5W9
Parkwood Institute, London Completed
London, Ontario, Canada, N6C 0A7
Hopital Montfort Completed
Ottawa, Ontario, Canada, K1K0T2
Thornhill Medical Centre Completed
Thornhill, Ontario, Canada, L4J 1E9
Canadian Phase Onward Inc. Recruiting
Toronto, Ontario, Canada, M3J 2C5
Contact: Afa Melik       Afa.melik@phaseonward.com   
Women's College Hospital Completed
Toronto, Ontario, Canada, M5S 1B2
Sinai Health System Completed
Toronto, Ontario, Canada, M5T 3L9
Centre for Addiction and Mental Health (CAMH) Recruiting
Toronto, Ontario, Canada, M6J 1H4
Contact: Robert Levitan, MD, MSc    416-535-8501 ext 4020    robert_levitan@camh.ca   
Principal Investigator: Robert Levitan, MD, MSc         
Sub-Investigator: Zafiris Jeffrey Daskalakis, MD, PhD         
Sub-Investigator: Daniel Mueller, MD, FRCPC         
Sub-Investigator: Peter Voore, MD, FRCPC         
Manna Research Recruiting
Toronto, Ontario, Canada, M9W 4L6
Contact: Kaitlin Halyk       Kaitlin.halyk@mannaresearch.com   
Sponsors and Collaborators
Assurex Health Inc.
Programs for Assessment of Technology in Health Research Institute
Centre for Addiction and Mental Health
Genome Canada
Assurex Health Ltd.
Mars Excellence in Clinical Innovation and Technology Evaluation
Investigators
Principal Investigator: James L Kennedy, MD Centre for Addiction and Mental Health
Principal Investigator: Bryan Dechairo, PhD Assurex Health Inc.
  More Information

Responsible Party: Ana Gugila, Sponsor, Assurex Health Inc.
ClinicalTrials.gov Identifier: NCT02466477     History of Changes
Other Study ID Numbers: EXCITE-013304-ARX1009.PTL
First Submitted: June 3, 2015
First Posted: June 9, 2015
Last Update Posted: October 12, 2017
Last Verified: October 2017

Keywords provided by Ana Gugila, Assurex Health Inc.:
Pharmacogenomic
Pharmacogenomic Testing
Pharmacogenomics
Genetic Testing
Genetics
Major Depressive Disorder
GeneSight
Enhanced GeneSight
Psychotropic

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Antipsychotic Agents
Psychotropic Drugs
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs